Related Experiment Video
Updated: May 25, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Pharmacological chaperone therapy for Fabry disease
1Department of Matrix Medicine, Faculty of Medicine, Oita University, Hasama-cho Idaigaoka 1-1, Yufu-shi, Oita 879-5593, Japan. ishiis01@oita-u.ac.jp
Summary
1-deoxygalactonojirimycin acts as a pharmacological chaperone, improving alpha-galactosidase A enzyme function in Fabry disease models. This therapy shows promise for patients with specific mutations, enhancing enzyme stability and reducing disease pathology.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Fabry disease is an inherited lysosomal storage disorder.
- Deficient alpha-galactosidase A activity causes disease pathology.
- Missense mutations often lead to misfolded enzyme proteins and endoplasmic reticulum retention.
Purpose of the Study:
- To investigate the potential of 1-deoxygalactonojirimycin as a pharmacological chaperone for Fabry disease.
- To assess the efficacy of 1-deoxygalactonojirimycin in improving mutant alpha-galactosidase A enzyme function and cellular trafficking.
Main Methods:
- Utilized 1-deoxygalactonojirimycin, an alpha-galactosidase A inhibitor, as a pharmacological chaperone.
- Administered 1-deoxygalactonojirimycin orally to transgenic mice expressing human mutant alpha-galactosidase A.
- Measured alpha-galactosidase A activity and globotriaosylceramide levels in various organs.
Main Results:
- 1-deoxygalactonojirimycin facilitated proper folding, stability, and lysosomal trafficking of mutant alpha-galactosidase A in mammalian cells.
- Oral administration in mice significantly increased alpha-galactosidase A activity in multiple organs.
- Concomitant reduction in globotriaosylceramide levels was observed in treated mice.
- Seventy-eight distinct missense mutations showed responsiveness to 1-deoxygalactonojirimycin treatment.
Conclusions:
- 1-deoxygalactonojirimycin demonstrates significant therapeutic potential as a pharmacological chaperone for Fabry disease.
- This approach may benefit a substantial number of patients with Fabry disease harboring responsive missense mutations.
- Pharmacological chaperone therapy offers a promising strategy for managing Fabry disease by improving mutant enzyme function.
Related Concept Videos
03:00Molecular Chaperones and Protein Folding
The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
The...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...